Zoe June Assaf
Senior Director, Cancer Genomics and Emerging Technologies Revolution Medicines
Zoe is a leader in translational medicine, with extensive experience driving the development of biomarker, technology, and computational strategies in oncology clinical development.
Her expertise includes integrating NGS-based technologies and advanced analytics into Phase I/II through registrational Phase III clinical trials, accelerating drug development and maximizing insights from biomarker programs.
She also brings deep experience in liquid biopsy and ctDNA applications, including prospective patient selection for clinical trials, treatment response monitoring to enable go/no-go decision making, and the identification of predictive and prognostic biomarkers to advance key translational medicine objectives.
Seminars
- What evidence and study designs are most critical to clinically validate liquid biopsies as early endpoints in trials, and how do these differ across indications?
- How can validated liquid biopsy endpoints improve patient selection and ongoing monitoring to accelerate therapeutic development and decision-making?
- What regulatory, operational, and data-standardization challenges still need to be addressed to ensure liquid biopsy endpoints are trusted and broadly adopted?
